Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib with or without metronomic oral vinorelbine as first-line therapy for EGFR-mutant advanced nonsquamous NSCLC
ChiCTR-IIR-17012197Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Aug 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of icotinib and vinorelbine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Aug 2017; status: not yet recruiting.
02
Drugs
icotinibvinorelbine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-IIR-17012197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17012197.